Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Zerbaxa (ceftolozane and tazobactam) by Year
Zerbaxa (ceftolozane and tazobactam) — Worldwide sales ($M) ($M)
Merck Zerbaxa (ceftolozane and tazobactam): $312M in FY2025, up 23.8% from a year earlier. That is the highest of the 8 years on record here.
Where the FY2025 figure comes from
“|| Zerbaxa | 82 | 77 | 159 | 70 | 74 | 145 | 81 | 87 | 312 | 4 | 2 | 10 | 8”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zerbaxa (ceftolozane and tazobactam) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 312 | +23.8% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 252 | +15.6% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 218 | +29.0% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 169 | -17,000.0% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | -1 | -100.8% | Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗ |
| FY2020 | Dec 31, 2020 | 130 | +7.4% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 121 | +39.1% | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2018 | Dec 31, 2018 | 87 | – | Form 10-K (filed 2021-02-25) ↗ |
Breakdown
What makes up zerbaxa (ceftolozane and tazobactam)
- Zerbaxa (ceftolozane and tazobactam) — U.S. sales ($M)186 · FY2025
- Zerbaxa (ceftolozane and tazobactam) — International sales ($M)126 · FY2025
- Zerbaxa (ceftolozane and tazobactam) — Worldwide reported growth YoY (%)24.0% · FY2025
- Zerbaxa (ceftolozane and tazobactam) — Worldwide constant-currency (ex-exchange) growth YoY (%)24.0% · FY2025
Cite this data
StockData. (2026). Merck Zerbaxa (ceftolozane and tazobactam) ($M), annual FY2018–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zerbaxa
See every metric in the Merck KPI table. Data updated Oct 26, 2026.